Stocksigma LogoStocksigma Logo

US FDA Concludes Inspection at Lupin鈥檚 Goa Facility with Form-483 Observation

Lupin Limited announced that the US FDA concluded an inspection at its manufacturing facility in Goa, India, conducted from 19th Oct'26 to 23rd Oct'26

US FDA Concludes Inspection at Lupin鈥檚 Goa Facility with Form-483 Observation

Lupin Ltd 路 Others (Uncategorized) 路 24 Oct 2026, 8:08 pm

US FDA Concludes Inspection at Lupin鈥檚 Goa Facility with Form-483 Observation Lupin Limited announced that the US FDA concluded an inspection at its manufacturing facility in Goa, India, conducted from 19th Oct'26 to 23rd Oct'26. The inspection closed with the issuance of a Form-483 with one observation. The company stated it will address the observation and respond to the US FDA within the stipulated timeframe, reiterating its commitment to maintaining CGMP compliance across all facilities.

Original exchange filing (PDF)

More announcements from Lupin Ltd

All Lupin Ltd announcements